Caris Life Sciences, Inc.
CAI
NASDAQ·Healthcare·Biotechnology·Mkt cap $7.1B
$25.07
▼ -0.99%
P/E
67.41
Mkt Cap
$7.1B
52-Wk Range
$14.19–$35.47
52-Week Range
$14.19 - $35.47
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 28.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI and machine learning algorithms for molecular data interpretation
- Comprehensive molecular profiling platform covering multiple cancer types
- Strategic partnerships with major biopharmaceutical companies
- Established clinical evidence base supporting treatment recommendations
Bear Case
2 risks
- Low volatility (beta 0.7).
- Growth premium of 9.0x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Growth
Stable outlook
Increasing adoption of precision medicine and personalized cancer treatment
Value
Growth premium of 9.0x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Momentum
Hot
+55.3% over 3m
Quality
Excellent
High-growth business (105% revenue growth, 70% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying CAI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$0.00 vs $0.01 consensus (-139.2% surprise). Revenue of $263.7M vs $238.1M expected (+10.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-139.2%
Revenue trend · last 8Q
—
—
+50%
+81%
+169%
+193%
+79%
+45%
Q1 24
Q2 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$80.7M
$100.0M
$120.9M
$181.4M
$216.8M
$292.9M
$216.2M
$263.7M
Margins · last 8Q
Gross
-53.6%
Operating
10.2%
Profit
-0.2%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 7, 2026
vs Industry
How CAI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related